Phase 2Completed
A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure
- Sponsor
- Mesoblast, Ltd. (Industry)
- Enrolment
- 60 enrolled
- Conditions
- Heart Failure
- Interventions
- Mesenchymal Precursor Cells (MPCs); Mesenchymal Precursor Cells (MPCs); Mesenchymal Precursor Cells (MPCs); standard-of-care treatment with mock mapping and injection procedures.; standard-of-care treatment with mock mapping and injection procedures.; standard-of-care treatment with mock mapping and injection procedures.
- Ages
- adults, older adults
- Registry
- NCT00721045
From the registry
This is a dose-ranging clinical study to evaluate the feasibility, safety, and tolerability of 3 different doses of immunoselected, culture expanded, nucleated, allogeneic MPCs in subjects who have cardiomyopathy of both ischemic and idiopathic etiology.
Primary outcomes
- The primary objective of this study is to evaluate the feasibility and safety of transendocardial injection using mapping Catheter with the Left Ventricular Injection Catheter of 25 M, 75 M, and 150 M allogeneic MPCs in subjects with heart failure.